GlassScriptPhysician profile
Viola Zilber
NPI 1881826162
$3,172.45
in general payments reported to CMS, 2019-2025
26 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $532 · 2022: $602 · 2023: $403 · 2024: $926 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,038.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,055.52 | 2021-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $611.95 | 2021-2025 | Breztri, Airsupra, Fasenra |
| Arcutis Biotherapeutics, INC. | $165.07 | 2024 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $159.87 | 2021-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $154.76 | 2022-2023 | |
| Pfizer INC. | $98.08 | 2021-2022 | |
| Amarin Pharma, INC. | $90.74 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $88.46 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $76.39 | 2022-2023 | |
| Kaleo, INC. | $72.97 | 2021-2022 | |
| Abbvie INC. | $70.00 | 2021-2024 | |
| Incyte Corporation | $66.17 | 2024-2025 | Opzelura |
| Genzyme Corporation | $57.95 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.76 | 2021-2022 | |
| Amgen INC. | $50.82 | 2025 | Tezspire |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $48.35 | 2021 | |
| Eisai INC. | $36.66 | 2021 | |
| Leo Pharma INC. | $36.47 | 2025 | Anzupgo, Adbry |
| Urovant Sciences INC | $29.29 | 2022 | |
| Aimmune Therapeutics, INC. | $26.93 | 2025 | Zenpep |
| Neurelis, INC. | $26.66 | 2022 | |
| Alk-Abello, INC | $22.67 | 2025 | Grastek, Ragwitek, Odactra |
| Axsome Therapeutics, INC. | $22.19 | 2025 | Symbravo |
| Vbi Vaccine (Delaware) INC. | $17.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.33 | 2021 | |
| Vistapharm, INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viola Zilber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.